Savient Pharmaceuticals, Inc. (SVNT) Provides Update On Closing Of Sale Of Global Biologics Manufacturing Business To Ferring B.V.
10/19/2005 5:09:21 PM
EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--June 24, 2005--Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, today announced that it expects the closing of the sale of its global biologics manufacturing business to Ferring to occur within the next 30 days.
Savient stated that all applicable regulatory filings have been submitted and that it has received clearance on three of the five required Israeli regulatory approvals, including anti-trust approval. Savient has provided all additional information requested by each of the remaining Israeli regulatory agencies.
comments powered by